Position in ERAS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,217,739
+$11,162,224 QoQ
Shares Held
693,309
+1610.9% QoQ
Ownership
0.223%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
6 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Point72 Asset Management, L.P. holds $2,392,275,927 across 187 Biotechnology names. ERAS ranks #58 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
4,183,918 | $168,319,021 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
225,510 | $118,047,719 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
3,229,939 | $102,453,665 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
846,801 | $73,646,282 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
424,750 | $71,791,245 | |
| 6 | ABVX |
Abivax S.A.
|
637,736 | $71,011,903 | |
| 7 | LEGN |
Legend Biotech Corp
|
3,886,017 | $70,298,047 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
358,634 | $67,799,757 |
All Filings in ERAS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,217,739 | 693,309 | Shares | Defined | 2026-05-15 | |
| 2025-03-31 | $55,515 | 40,522 | Shares | Defined | 2025-07-21 | |
| 2024-09-30 | $173,625 | 63,599 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $2,443,135 | 1,035,227 | Shares | Defined | 2024-09-16 | |
| 2024-03-31 | $2,258,283 | 1,096,254 | Shares | Defined | 2024-05-15 | |
| 2023-03-31 | $106,848 | 35,498 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||